Pharmamarketeer
wet- en regelgeving

EMA’s PRAC committee recommends Xeljanz to be used with caution for all patients at high risk of blood clots

4 november 2019
Pharma Biz

A review by the European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) committee has concluded that Xeljanz (tofacitinib) could increase the risk of blood clots in the lungs and in deep veins in patients who are already at high risk.

Ook interessant voor je

Medhc-fases-banner
Advertentie(s)